Finance

Lists
Q1 2027 earnings • released • Revenue beat +5.25%
See results
4527:TYO
Rohto Pharmaceutical Co Ltd
Â¥2,862.50
+21.16%
(+500.00) 1D
Aug 7, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4527...
Open
Â¥2,651
High
Â¥2,862
Low
Â¥2,650
Mkt. cap
676.06B
Avg. vol.
1.00M
Volume
8.14M
Dividend
1.61%
Quarterly dividend
Â¥12
Ex-dividend date
Sep 29, 2026
P/E ratio
19.72
52-wk high
Â¥2,862
52-wk low
Â¥2,218
EPS
Â¥145
Shares outstanding
113.97M
No. of employees
9K
Open
Â¥2,651
High
Â¥2,862
Low
Â¥2,650
Mkt. cap
676.06B
Avg. vol.
1.00M
Volume
8.14M
Dividend
1.61%
Quarterly dividend
Â¥12
Ex-dividend date
Sep 29, 2026
P/E ratio
19.72
52-wk high
Â¥2,862
52-wk low
Â¥2,218
EPS
Â¥145
Shares outstanding
113.97M
No. of employees
9K
News stories
From sources across the web
Profile
Rohto Pharmaceutical Co., Ltd. is a Japanese multinational corporation specializing in fast-moving consumer goods and pharmaceuticals, headquartered in Ikuno-ku, Osaka, Japan. The company primary focuses on skin and eye care products. They also produce cosmetics, supplements, and over-the-counter medications. Wikipedia
About Rohto Pharmaceutical Co Ltd
CEOKunio Yamada | Kunio Yamada
Employees9.29K
Founded1899
HeadquartersOsaka, Osaka, Japan
SectorPersonal care products
Last report
Aug 6, 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
91.62B / 87.05B
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
82.29B
88.81B
90.65B
91.62B
Cost of goods sold
36.96B
37.68B
40.28B
40.03B
Cost of revenue
36.96B
37.68B
40.28B
40.03B
Research and development expenses
-
-
13.73B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37.71B
36.88B
19.39B
37.93B
Operating expense
37.83B
37.03B
42.90B
37.93B
Total operating expenses
74.79B
74.71B
83.18B
77.96B
Operating income
7.50B
14.10B
7.47B
13.66B
Other non operating income
439.00M
116.00M
445.00M
60.00M
EBT including unusual items
8.47B
15.22B
8.06B
14.80B
EBT excluding unusual items
8.48B
15.24B
8.12B
14.49B
Income tax expense
2.75B
4.65B
1.98B
3.75B
Effective tax rate
32.50%
30.55%
24.58%
25.36%
Other operating expenses
-
-
-
-
Net income
5.88B
10.63B
5.97B
10.65B
Net profit margin
7.15%
11.97%
6.58%
11.62%
Earnings per share
-
-
-
-
Interest and investment income
270.00M
573.00M
759.00M
1.15B
Interest expense
-286.00M
-311.00M
-371.00M
-320.00M
Net interest expenses
-16.00M
262.00M
388.00M
833.00M
Depreciation and amortization charges
-
-
7.69B
-
EBITDA
11.54B
17.39B
11.82B
18.01B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps